Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

European journal of neurology·2026
Same author

Donor-specific pathological features associate with genetic background, lesion type distribution, and clinical heterogeneity in multiple sclerosis.

Acta neuropathologica·2026
Same author

Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.

Neurology·2026
Same author

Microglial states associate with lesion dynamics in multiple sclerosis.

Cell reports·2026
Same author

Human microglial transitions at the Aβ-tau inflection point associate with divergent pathways to dementia and resilience.

Nature medicine·2026
Same author

Foamy microglia link oxylipins to disease progression in multiple sclerosis.

Nature neuroscience·2026

Related Experiment Video

Updated: Jun 19, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Restoring immune suppression in the multiple sclerosis brain.

Nathalie Koning1, Bernard M J Uitdehaag, Inge Huitinga

  • 1Netherlands Institute for Neuroscience, Amsterdam, The Netherlands.

Progress in Neurobiology
|October 6, 2009
PubMed
Summary

Current multiple sclerosis therapies are insufficient. Targeting myeloid cells, specifically macrophages and microglia, offers a novel therapeutic approach. The CD200-CD200R interaction shows promise for suppressing inflammation and restoring immune balance in the brain.

More Related Videos

Simultaneous Isolation of Principal Central Nervous System-Resident Cell Types from Adult Autoimmune Encephalomyelitis Mice
08:49

Simultaneous Isolation of Principal Central Nervous System-Resident Cell Types from Adult Autoimmune Encephalomyelitis Mice

Published on: October 6, 2023

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Related Experiment Videos

Last Updated: Jun 19, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Simultaneous Isolation of Principal Central Nervous System-Resident Cell Types from Adult Autoimmune Encephalomyelitis Mice
08:49

Simultaneous Isolation of Principal Central Nervous System-Resident Cell Types from Adult Autoimmune Encephalomyelitis Mice

Published on: October 6, 2023

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

Area of Science:

  • Neuroimmunology
  • Inflammatory demyelinating diseases

Background:

  • Multiple sclerosis (MS) is a disabling inflammatory brain disease with unknown causes.
  • Current MS treatments partially manage disease activity but do not halt progression or cure the condition.
  • Existing therapies primarily target T cells, yet also impact myeloid cells like macrophages and microglia.

Purpose of the Study:

  • To review current therapeutic strategies for MS.
  • To highlight the role of myeloid cell phagocytosis in MS lesion development and progression.
  • To propose novel therapeutic targets focused on modulating myeloid cell activation and phagocytosis.

Main Methods:

  • Review of existing literature on MS therapies.
  • Analysis of the role of myeloid cell phagocytosis in MS pathogenesis.
  • Discussion of potential therapeutic targets: complement receptor 3, CD47-SIRPalpha, and CD200-CD200R interactions.

Main Results:

  • Myelin phagocytosis by macrophages and microglia is crucial for MS lesion development.
  • Complement receptor 3, CD47-SIRPalpha, and CD200-CD200R are potential targets for myeloid cell modulation.
  • The CD200-CD200R interaction appears to be the most specific target for suppressing excessive myeloid activation.

Conclusions:

  • Novel MS therapies should target myeloid cell activation and phagocytosis.
  • Modulating myeloid cells, particularly via the CD200-CD200R pathway, could restore immune suppression in MS.
  • Targeting myeloid cell interactions offers a promising strategy to improve MS treatment outcomes.